AnTolRx

AnTolRx is a biotechnology and healthcare startup founded in 2015, pioneering innovative therapies for autoimmune diseases. The company's slogan, "Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary nanoparticle-based solutions," encapsulates its mission. AnTolRx's approach involves developing nanoparticle-based treatments to achieve antigen-specific immune tolerance, addressing the limitations of traditional therapies that can cause severe side effects by broadly suppressing the immune system. The company's proprietary drug development technique specifically targets harmful immune cells, delivering a unique tolerogenic signal to induce an anti-inflammatory response. AnTolRx secured a significant $4.00M Series A investment on 08 September 2016 from notable investors including Orion Healthcare Equity Partners, JDRF (The Juvenile Diabetes Research Foundation), and Pfizer Venture Investments. This funding serves as a testament to the confidence these industry players have in AnTolRx's pioneering approach and potential to revolutionize autoimmune disease treatment.